Behavioral support for first-time users of a continuous glucose monitoring (CGM) device showed no significant difference in reduction of A1c levels compared with CGM alone in the management of type 1 ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

One-year data suggest allogeneic stem cell-derived islet-cell therapy could become a future option for those with type 1 ...

Do you hope your child will follow in your footsteps and become a doctor? Or would you urge them to choose a different path?

Highlights from ASCO 2025 in early-stage NSCLC include updates on CheckMate 816 on neoadjuvant nivolumab, NeoADAURA on osimertinib, and data on low-dose CT screening, presented by Dr Jonathan Goldman.

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Two weeks of CGM use can give people with type 2 diabetes who are not on insulin helpful, personalized insights into how lifestyle factors affect their blood sugar levels.

The drug promotes lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis.

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.

Zemcelpro provides an option for people with a hematologic malignancy who need a blood stem cell transplant but have no ...

The dapivirine ring was originally approved in July 2020 to reduce the risk for HIV-1 infection in women 18 years and older ...